Smith & Nephew heads into its June 9 trading update with the lending market flashing its tightest signal in months — a more charged setup than the muted price action suggests.
The borrow story is striking. Availability has collapsed to just 1.9% of short interest — meaning almost every share in the lending pool is already out on loan, touching levels that have been near zero for most of the past three weeks. That's a dramatic swing from late April, when availability ran above 27%. Cost to borrow has climbed in parallel, rising roughly 23% over the past month to 5.4%. Neither figure is extreme in absolute terms, but the speed of the tightening is notable: the borrow market went from comfortable to effectively maxed out in the span of a fortnight. Options positioning, by contrast, offers no alarm signal — the put/call ratio is running below its 20-day average at 0.19, fractionally on the bullish side.
The bull and bear cases heading into the print are well-defined. Bulls point to 5.5% underlying growth in orthopaedics, strong CORI robotic placement numbers in the US, and management's guidance for a margin improvement skew toward the second half of the year. Bears focus on China: inventory headwinds and reimbursement pressure in that market have been a persistent drag, and the orthopedics segment's return on invested capital remains materially below the sports medicine and wound care divisions. The analyst community has been tilting more cautious — Canaccord trimmed its target to $30 in May, essentially at the current price of $30.61, while Bernstein downgraded the stock to Market Perform in late 2025. The consensus price target data in this snapshot predates current coverage and should be disregarded.
The institutional picture adds one genuinely interesting thread. Cevian Capital — the Swedish activist fund — reported holding 11.8% of the company as of June 2, with a 15.3 million share addition in the most recent filing. That is not a passive position. Cevian's continued accumulation puts execution pressure on management to demonstrate margin progress: the fund's presence typically signals an expectation of operational improvement or strategic action. Several other active managers, including Causeway and UBS Asset Management, also added meaningfully in the last reporting period.
Past prints have been subdued on the day — the stock fell just 0.4% and 1.1% respectively after the two most recent events — though the five-day drift showed more variance, including a 7.6% decline after the March 2026 release. Tuesday's update tests whether the margin improvement story management promised for H2 is on track, and whether the China drag has stabilised enough to leave full-year guidance intact.
See the live data behind this article on ORTEX.
Open SNN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
